Health-e (Cape Town)

Africa: The Stavudine Debate

At the opening of the SA HIV Clinicians Society there was an excellent debate on the stavudine (also known as d4T) 20mg trial. Francois Venter argued for and Eric Goemaere against. Dozens of Treatment Action Campaign members demonstrated against the trial and participated in the debate.

Stavudine is an antiretroviral drug that is widely used in Sub-Saharan Africa but barely used at all in North America and Europe. It is much cheaper than other first-line antiretrovirals in use but it has terrible side-effects: lipoatrophy, peripheral neuropathy and, quite rarely, fatal lactic acidosis and pancreatitis.

Currently stavudine is dispensed in 30mg doses. The proposed trial, which has received ethical approval and is funded by the Gates Foundation, will compare stavudine 20mg against the current standard of care drug that replaced it, tenofovir. The aim is to see if the lower dose is still effective and has an acceptable side effect profile. This is called a non-inferiority trial. In other words it will test if stavudine at 20mg is no worse than tenofovir. No one sensible believes there's a realistic chance of stavudine at 20mg doing better than tenofovir.

Venter wants to run the trial because he is concerned that although there is a drive to reduce the uptake of stavudine in Sub-Saharan Africa, the low cost of the drug means that it will be around for many years and we should find a safer dose if possible. Venter says that international cuts in AIDS treatment funding strengthen the case for the trial.

Many clinicians and activists oppose the trial because we think stavudine 20mg is below the standard of care and that the trial won't answer questions about the drug's long-term toxicity because it will only run for 96 weeks.

If I was about to start antiretroviral treatment I would want to take the best regimen available to me. In South Africa, patients attending the public health system who start antiretroviral treatment get tenofovir, so choosing a drug like stavudine with its side effect profile would be very risky, even at a lower dose, with no potential advantage over tenofovir. This in a nutshell is why I am opposed to the trial.

Graeme Meintjes, one of the debate panelists, made an important point: For some drugs, there is a threshold below which some side effects disappear. For other drugs there are fewer side effects, but they reduce more or less linearly with the reduction in the dose. Meintjes said that before a trial like this can begin there needs to be pre-clinical evidence showing whether stavudine's worst side effects are of the former or the latter variety. If pre-clinical trial evidence shows that stavudine's most serious side effects merely diminish linearly but do not disappear at 20mg then the trial should not proceed because it would definitely be a worse option than tenofovir. The balance of evidence we have from previous reductions in stavudine's dosing shows that a drop to 20mg is likely to have a more or less linear and not a threshold effect on the side effects.

Eric Goemaere proposed an interesting compromise. There are several hundred thousand people in South Africa still on stavudine 30mg. Patients on 30mg who are currently not experiencing any stavudine-related side-effects (and there are many of them) might very well have an interest in participating in a trial that sees if they can maintain suppression of HIV at a lower dose. Such a trial would not be offering patients an intervention known to likely be worse than their current standard of care. If HIV remained suppressed for patients taking 20mg, every patient in South Africa who takes stavudine 30mg could reduce their dose. If I were taking stavudine 30mg and I was not experiencing peripheral neuropathy or lipoatrophy I might very well be prepared to participate in such a trial.

However, Polly Clayden of HIV i-Base made a point to me which is hard to counter, "You're middle-class with access to the best medical care. If you had been initiated on stavudine, you would have switched to tenofovir years ago."

There is a fundamentally important ethical principle that Clayden is insisting upon here and I think it is unanswerable. You have to put yourself in the place of a patient who qualifies for a clinical trial and then decide what choice would you ideally make?1 Nevertheless, given a choice between the trial currently on the table and this modified version, I find the latter more palatable.

The debate was excellent and it bodes well for South African medical science that there has been such strong community engagement and interest in this.

There are similarities between this approach and John Rawls Original Position, Kant's Categorical Imperative and the maxim of Do to others as you'd want done to yourself. All these concepts are subtly different, but they have a common underpinning that is very compelling: they ask you to use your empathy faculty, to put yourself in a scenario and to use reason to reach a decision and to then apply that decision universally. Of course, these approaches are not without problems. For one thing it is impossible to know with certainty what you would do in a particular situation until you are in it. Incidentally, it is by application of the same principle that I support pre-approval access to the incompletely tested and not yet approved TB drug bedaquiline: If I had drug-resistant TB, I'd want to take it, because the alternatives appear worse.

Ads by Google

Copyright © 2012 Health-e. All rights reserved. Distributed by AllAfrica Global Media (allAfrica.com). To contact the copyright holder directly for corrections — or for permission to republish or make other authorized use of this material, click here.

AllAfrica publishes around 2,000 reports a day from more than 130 news organizations and over 200 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.